Department Of Neurooncology
Investigator
Fabio Iwamoto, MD
Email
fi2146@cumc.columbia.edu

Dr. Iwamoto is a neuro-oncologist whose previous training includes a neurology residency at NewYork-Presbyterian/Weill Cornell Medical Center and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. For over three years, Dr. Iwamoto was an attending physician and an investigator at the Neuro-oncology Branch, a trans-institute branch of the National Cancer Institute and National Institute of Neurological Disorders and Stroke, in Bethesda, MD. At the intramural NIH, Dr. Iwamoto was a principal investigator in early phase clinical trials for brain tumors and worked with laboratory and computational scientists on several translational projects in brain tumors.

Dr. Iwamoto was recruited to Columbia University as the Deputy Director of the Neuro-oncology Division and is actively developing the clinical and translational research components of this program. He is an expert in the diagnosis, management, and treatment of brain and spinal cord tumors as well as neurological complications of cancer.

Clinical Studies Managed By This Investigator:
Condition Study Title
Brain Tumors [ CLOSED ] A study for elderly individuals with malignant brain tumors using experimental drug, bevacizumab combined with temozolomide
Brain Tumors [ CLOSED ] A study for adult patients with recurrent glioblastoma multiforme using study drug SL-701
Solid Tumors [ CLOSED ] A study for patients with advanced refractory solid tumors using study drug Varlilumab
Brain Tumors [ CLOSED ] A study for patients with glioblastoma using study drug ICT-107
Brain Tumors [ CLOSED ] A study for patients with recurrent glioblastoma or anaplastic astrocytoma using study drug Toca 511
Brain Tumors [ CLOSED ] A study for patients with MGMT-Methylated Glioblastoma using study drug temozolomide
Brain Tumors [ CLOSED ] A study for patients with glioblastoma using study drub nivolumab
Lymphoma [ CLOSED ] A study for patients with Central Nervous System Lymphoma (PCNSL) or Primary Testicular Lymphoma (PTL) using study drug Nivolumab
Brain Tumors [ CLOSED ] Study of Nivolumab (Study Drug) for Recurrent or Progressive IDH Mutant Gliomas
Cancer [ CLOSED ] A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Brain Tumors [ CLOSED ] Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Cancer Study of ST101 in Patients with Advanced Solid Tumors
Brain Tumors Study of Tumor Treating Fields (Optune, 200kHz) with Radiation Therapy and Temozolomide for Treatment of Newly Diagnosed Glioblastoma
Brain Tumors Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects
Brain Tumors ImmuneSense Study: IGV-001 in Newly Diagnosed Patients With Glioblastoma
Brain Cancer Study of Tumor Treating Fields (Optune, 200kHz) with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Brain Cancer Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects
Brain Cancer ImmuneSense Study: IGV-001 in Newly Diagnosed Patients With Glioblastoma
Brain Cancer Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM)
Brain Tumors Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM)
Brain Cancer Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma)
Brain Tumors Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma)
Lymphoma Study of Pembrolizumab, Ibrutinib and Rituximab in Patients with Primary Central Nervous System Lymphoma (PCNSL)